Unlock instant, AI-driven research and patent intelligence for your innovation.

Synergistic treatment of cells that express EPHA2 and ERBB2

A cell and cancer cell technology, applied in the field of synergistic therapy of cells expressing EPHA2 and ERBB2, which can solve problems such as inconsistent gene amplification

Inactive Publication Date: 2010-12-15
MEDIMMUNE LLC +1
View PDF184 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0026] HER2 overexpression has also been observed in other cancers including gastric, endometrial, salivary gland, lung, kidney, colon, thyroid, pancreas, and bladder (often overexpressed, but inconsistently due to gene amplification)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synergistic treatment of cells that express EPHA2 and ERBB2
  • Synergistic treatment of cells that express EPHA2 and ERBB2
  • Synergistic treatment of cells that express EPHA2 and ERBB2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0053] Embodiments of the invention are provided in the following numbered embodiments:

[0054] 1. A method of reducing hyperproliferative cell proliferation, said method comprising:

[0055] a) identifying a population of hyperproliferative cells expressing EphA2 and ErbB2; and

[0056] b) administering an agent targeting EphA2.

[0057] 2. A method of reducing proliferation of a population of hyperproliferative cells expressing EphA2 and ErbB2, said method comprising administering an agent targeting EphA2.

[0058] 3. A method of reducing the proliferation of a population of hyperproliferative cells expressing EphA2 and ErbB2, said method comprising administering an agent that inhibits, blocks or interferes with the interaction of EphA2 and ErbB2.

[0059] 4. The method of any one of embodiments 1-3, wherein the hyperproliferative cells are cancer cells.

[0060] 5. The method of embodiment 4, wherein the cancer is skin cancer, lung cancer, colon cancer, breast cancer, p...

Embodiment 1

[0299] Reagents: Antibodies against the following proteins were used: EphA2 (Zymed Laboratories, Burlingame, CA; Santa Cruz Biotechnology; Santa Cruz, CA) ; Upstate Biotechnology, Lake Placid, NY), EphA4 (Upstate Biotechnology, Lake Placid, NY), proliferating cell nuclear antigen (PCNA); BD Biotechnology, Franklin Lakes, NJ Scientific Corporation (BD Biosciences, Franklin Lakes, NJ)), anti-Erk, anti-phosphothreonine-202 / tyrosine-204Erk, Akt, phosphorylated serine-473Akt (Cell Signaling Technologies, Inc., Boston, MA (Cell Signaling Technology, Boston, MA), Anti-Tubulin (Sigma-Aldrich, St.Louis, MO), ErbB2 (Neolabel / La, Fremont, CA) Vision Corporation (Neomarkers / Lab Vision Corporation, Fremont, CA)), anti-b-actin (Santa Cruz Biosciences), Ras (BD Biosciences), RhoA (Santa Cruz Biosciences; BD Biosciences ), von Willebrand factor (vWF; Zymed Laboratories, South San Francisco, CA), E-cadherin (BD Biosciences), Ki67 (Mass. Vision Biosystems Inc., Norwell, MA) and normal rabbit ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to methods of treating hyperproliferative cells that express EphA2 and ErbB2. The present invention further relates to methods of selecting patient populations for treatment methodologies.

Description

[0001] Claims of Inventions Made Under Federally Sponsored Research and Development [0002] This invention was made with US Government support under grant numbers CA95004, CA114301, and CA1179151-02 from the National Institutes of Health and grant number W81XWH-05-01-0254 from the Department of Defense. The United States Government may have certain rights in this invention. [0003] Cross References to Related Applications [0004] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 60 / 929,212, filed June 18, 2007. This prior application is hereby incorporated by reference in its entirety for all purposes. technical field [0005] The present invention provides methods of treating hyperproliferative cells expressing EphA2 and ErbB2. The invention also provides methods of selecting patient populations for treatment. Background of the invention [0006] cancer [0007] A neoplasia or tumor is a mass of abnormal, uncontrolled gr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCA61K31/7105G01N2333/485G01N33/57492G01N2800/52G01N2333/475A61P1/00A61P11/00A61P11/06A61P17/00A61P17/06A61P17/08A61P35/00A61P9/00A61P9/10
Inventor D·布兰特利-赛德J·陈E·布鲁克海默D·杰克逊
Owner MEDIMMUNE LLC